Document Detail


Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis.
MedLine Citation:
PMID:  19733721     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Traditional nonsteroidal anti-inflammatory drugs are associated with the destabilization of blood pressure (BP) control, particularly in hypertensive patients treated with blockers of the renin-angiotensin system. To assess the potential impact of nitric oxide donation, the effects of naproxcinod with naproxen and placebo on changes in BP were compared in a randomized clinical trial of 916 patients with osteoarthritis after 13 weeks of therapy. In addition, the effects of naproxcinod versus naproxen and placebo on systolic BP in patients with hypertension treated with renin-angiotensin system blockers were evaluated. Naproxcinod 750 mg twice daily reduced systolic BP compared to naproxen 500 mg twice daily (p <0.02). The 2 doses of naproxcinod showed reductions from baseline in diastolic BP relative to naproxen (p <0.04) and similar changes compared to placebo. In 207 patients with hypertension treated with renin-angiotensin-blocking agents alone or with diuretics, the difference in mean change from baseline in systolic BP between naproxen 500 mg and naproxcinod 750 mg was 6.5 mm Hg in favor of naproxcinod (p <0.02). The proportion of patients in the overall population with systolic BP increases > or =10 mm Hg was greater with naproxen 500 mg (22%) compared to naproxcinod 750 mg (14%, p = 0.04), naproxcinod 375 mg (14%, p = 0.055), and placebo (15.6%, p = 0.155). In conclusion, naproxcinod did not induce elevations of BP seen with naproxen, and it had similar effects on BP to that of placebo in patients with osteoarthritis.
Authors:
William B White; Thomas J Schnitzer; Rosanna Fleming; Brigitte Duquesroix; Maarten Beekman
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of cardiology     Volume:  104     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-07     Completed Date:  2009-09-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  840-5     Citation Subset:  AIM; IM    
Affiliation:
Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA. wwhite@nso1.uchc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage,  pharmacology*,  therapeutic use
Blood Pressure / drug effects*,  physiology
Comorbidity
Double-Blind Method
Female
Humans
Hypertension / drug therapy,  epidemiology*
Male
Middle Aged
Naproxen / administration & dosage,  analogs & derivatives*,  pharmacology*
Nitric Oxide Donors / administration & dosage,  pharmacology*
Osteoarthritis / epidemiology*,  physiopathology
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Nitric Oxide Donors; 0/naproxen-n-butyl nitrate; 22204-53-1/Naproxen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Next Document:  Effect of balloon valvuloplasty in patients with severe aortic stenosis on levels of N-terminal pro-...